Physician Views snap-poll: Asking US ophthalmologists to assess Novartis' newly approved Beovu

Earlier this month, the FDA approved Novartis' Beovu for the treatment of wet age-related macular degeneration (AMD), pitching it as a potential competitor to Regeneron Pharmaceuticals' blockbuster therapy Eylea.

Analysis - KOL Views Results: Leading retinal specialist expects a slow rollout but sees big potential in Novartis’ Beovu

We are snap-polling US-based ophthalmologists to gauge how they perceive Beovu, its clinical profile and potential impact on the treatment landscape. Results from this snap-poll will be published later this week for FirstWord Pharma PLUS subscribers.

_____________

Q. Do you routinely treat wet age-related macular degeneration (AMD)?

Yes

No

_____________

Q. The FDA has approved Beovu (brolucizumab) injection for the treatment of wet AMD. It is the first approved anti-VEGF to offer both greater fluid resolution versus Eylea (aflibercept) and the ability to maintain eligible wet AMD patients on a three-month dosing interval immediately after a three-month loading phase with uncompromised efficacy.

Approval was based on findings from the Phase III HAWK and HARRIER clinical trials, in which Beovu demonstrated non-inferiority versus Eylea in mean change in best-corrected visual acuity (BCVA) at year one. In both clinical trials, approximately 30% of patients gained at least 15 letters at year one. Beovu showed greater reduction in central subfield thickness (CST) as early as week 16 and at year one, and fewer patients had intra-retinal (IRF) and/or sub-retinal fluid (SRF).

At year one, over half of patients treated with Beovu were maintained on a three-month dosing interval (56% in HAWK and 51% in HARRIER). The remaining patients in the study were treated on a two-month dosing schedule. Beovu exhibited an overall safety profile comparable to Eylea.

How would you rate the clinical innovation of this product versus current standard-of-care therapy?

1 - None

2

3

4 - Moderate

5

6

7 - Very high

_____________

Q. How would you rate this product as meeting an unmet clinical need?

1 - None

2

3

4 - Moderate

5

6

7 - Very high

_____________

Q. How would you rate your likelihood of using this product (based on the strength of available clinical data) now it has been approved?

1 - None

2

3

4 - Moderate

5

6

7 - Very high

_____________

Q. Assuming real world-use confirms the clinical profile of this drug (as per its clinical study data), how frequently would you expect to use versus current standard-of-care therapy?

1 - None

2

3

4 - Moderately

5

6

7 - Very frequently

_____________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.